Castle Biosciences, Inc.

Castle Biosciences, Inc. is a leading molecular diagnostics company dedicated to improving health outcomes through innovative tests that guide patient care. The company's mission is to transform disease management by providing personalized, clinically actionable genomic information, enabling healthcare providers and patients to make more informed decisions. Headquartered in Friendswood, Texas, Castle Biosciences also operates clinical laboratories in Phoenix, Arizona, and Pittsburgh, Pennsylvania.

Castle Biosciences offers a portfolio of proprietary molecular diagnostic tests, primarily gene expression profile (GEP) tests, across dermatology, gastroenterology, and ophthalmology. Key products include DecisionDx-Melanoma for invasive cutaneous melanoma, TissueCypher Barrett's Esophagus to predict progression to esophageal cancer, DecisionDx-SCC for cutaneous squamous cell carcinoma, DecisionDx-UM for uveal melanoma, and MyPath Melanoma for difficult-to-diagnose melanocytic lesions. The company also recently launched AdvanceAD-Tx to guide systemic treatment selection for moderate-to-severe atopic dermatitis.

Under the leadership of Founder, President, and CEO Derek Maetzold, Castle Biosciences maintains a strong market position in its specialized diagnostic areas. The company reported strong full-year 2025 revenue, exceeding guidance, with significant growth in core test volumes. In March 2026, Castle Biosciences celebrated the grand opening of its new corporate headquarters in Friendswood, Texas, and for the fifth consecutive year, earned the USA TODAY Top Workplaces Award. Recent data presentations continue to highlight the utility of its tests, such as DecisionDx-Melanoma, in identifying high-risk patients.